Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

JAB-21822

Phase 3Small molecule

JJacobio Pharmaceuticals Co., Ltd.

JAB-21822 is one of 47 small molecule programs targeting NSCLC. It is currently in Phase 3.

3

Indications

5

Total Trials

3

Active Trials

46

Competitors

Pipeline

Status by Indication[3][1]

Indication

NSCLCActive, not recruiting

Advanced Non-Squamous Non-Small-Cell Lung CancerRecruiting

KRAS P.G12CRecruiting

NSCLCPreclinical

Active, not recruiting

Advanced Non-Squamous Non-Small-Cell Lung CancerPhase 3

Recruiting

KRAS P.G12CPreclinical

Recruiting

Competition

Competitive Landscape

55 competitors in NSCLC

#DrugCompanyPhaseTrials

Iressa

Taxotere

Alimta

Navmi

SSummit Therapeutics

Taxol

Tecentriq

Alecensa

Libtayo

SYS6010

CCSPC Megalith Biopharmaceutical Co.,Ltd.

Firmonertinib

AAllist Pharmaceuticals, Inc.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

PreclinicalActive, not recruiting

NSCLC

NCT05009329

Q1 2027

PreclinicalRecruiting

KRAS P.G12C

NCT05288205

Q3 2030

Phase 3Recruiting

Advanced Non-Squamous Non-Small-Cell Lung Cancer

NCT06416410

Clinical

Trials by Indication[1]

Patients With Advanced Solid Tumors1 trial

JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation

Completed·JJacobio Pharmaceuticals Co., Ltd.·Phase 1/2·NCT05002270·29 enrolled

KRAS P.G12C1 trial

A Phase 1/2a Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of JAB-21822 in Combination With JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation

Recruiting·AAllist Pharmaceuticals, Inc.·Preclinical·NCT05288205·240 enrolled

Advanced Non-squamous Non-small-cell Lung Cancer1 trial

An Open-label, Randomized, Positive Control, Multicenter Phase III Clinical Study. Evaluating JAB-21822 Combined With JAB-3312 Compared Tislelizumab Combined With Pemetrexed + Carboplatin in the First Line for Treatment of Advanced Non-squamous Non-small Cell Lung Cancer With KRAS p.G12C Mutation

Recruiting·AAllist Pharmaceuticals, Inc.·Phase 3·NCT06416410·392 enrolled

NSCLC1 trial

Multi-center, Open, Dose-escalation, and Expanded Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of JAB-21822 in Advanced Solid Tumors With KRAS p.G12C Mutation

Active, not recruiting·AAllist Pharmaceuticals, Inc.·Preclinical·NCT05009329·315 enrolled

Unspecified1 trial

Mass Balance Study of [14C]JAB-21822

Completed·AAllist Pharmaceuticals, Inc.·Phase 1·NCT05920941·6 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for JAB-21822. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — JAB-21822 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for JAB-21822. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jacobio Pharmaceuticals Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: JJacobio Pharmaceuticals Co., Ltd.

Related News